All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2024-02-14T16:06:38.000Z

The QUIWI trial: What is the potential of quizartinib in patients with wild-type FLT3?

Feb 14, 2024
Share:

Bookmark this article

During the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, the AML Hub spoke to Adrian Mosquera Orgueira, Santiago Clinic Hospital CHUS, Santiago, ES. We asked, The QUIWI trial: What is the potential of quizartinib in patients with wild-type FLT3? 

The QUIWI trial: What is the potential of quizartinib in patients with wild-type FLT3?

Mosquera Orguiera provides an overview of the phase II QUIWI trial (NCT04107727) investigating the addition of quizartinib, an FLT3 inhibitor, to standard chemotherapy vs placebo in patients aged 18–70 years with newly diagnosed FLT3-internal tandem duplication wild-type acute myeloid leukemia. He then highlights the initial results, which suggest that quizartinib is associated with a survival benefit vs placebo in this patient population. Mosquera Orguiera concludes by discussing a biological correlative analysis, indicating that gene expression signatures linked with an FLT3-internal tandem duplication may predict response to quizartinib. 

Newsletter

Subscribe to get the best content related to AML delivered to your inbox